2026 Atlanta Genitourinary Cancers Summit

Accreditation: 6.75 AMA PRA Category 1 Credit™ | 6.75 Nursing Contact Hours | 6.75 ACPE Pharmacy | 6.75 ABIM MOC II

Venue: Grand Hyatt Atlanta in Buckhead, Peachtree Road Northeast, Atlanta, GA, United States

Start Date: March 14, 2026

Faculty disclosures

Identification and mitigation of potential conflicts of interest

All conflict of interest has been identified and mitigated for individuals in control of contents.

Planning committee disclosure statement

None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.

Conference Chairs

has a financial relationship (Professional Services) with Incyte, BMS, Kyowa Kirin, Eisai, Exelixis.

has a financial relationship (Grant Or Contract) with Merck, Xencor, Bayer, Bristol-Myers Squibb, Genentech/Roche, SeaGen, Incyte, Nektar, AstraZeneca, Tricon Pharmaceuticals, Exelixis, Nikang, Loxo Oncology, Ambrx, Regeneron, Acrivon Therapeutics, Amgen, Genome & Company, AAA, Peloton Therapeutics, Pfizer; financial relationship (Other) with Exelixis, Bayer, BMS, Eisai, Pfizer, AstraZeneca, Janssen, Calithera Biosciences, Genomic Health, Nektar, EMD Serono, SeaGen, and Sanofi.

Session Chairs

has a financial relationship (Grant Or Contract) with Exelixis.

has a financial relationship (Grant Or Contract) with Arnold Ventures; financial relationship (Consultant) with Biofourmis; financial relationship (Consultant) with Cancer Study Group; financial relationship (Consultant) with ConcertAI; financial relationship (Ownership Interest) with Counsel Health; financial relationship (Grant Or Contract) with Emerson Collective; financial relationship (Ownership Interest) with GNS Healthcare; financial relationship (Consultant) with Humana; financial relationship (Ownership Interest) with Main Street Health; financial relationship (Consultant) with Main Street Health; financial relationship (Grant Or Contract) with Mendel; financial relationship (Consultant) with Mendel.ai; financial relationship (Consultant) with Nanology; financial relationship (Ownership Interest) with Onc.ai; financial relationship (Consultant) with Onc.ai; financial relationship (Consultant) with Optinosis; financial relationship (Ownership Interest) with Scaled Insights; financial relationship (Grant Or Contract) with Schmidt Futures; financial relationship (Consultant) with Thyme Care; financial relationship (Ownership Interest) with Thyme Care.

Awaiting faculty disclosure.

has a financial relationship (Speaker) with Astrazeneca; financial relationship (Speaker) with Caris; financial relationship (Speaker) with Cumberland; financial relationship (Advisor) with Exelexis; financial relationship (Speaker) with Exelexis; financial relationship (Advisor) with Guardant; financial relationship (Speaker) with Guardant health; financial relationship (Speaker) with Incyte; financial relationship (Speaker) with Jazz pharmaceuticals; financial relationship (Speaker) with Merck; financial relationship (Speaker) with Pfizer.

has a financial relationship (Professional Services) with Blue Earth Diagnostics; financial relationship (Professional Service) with CG Oncology; financial relationship (Professional Services) with Engene; financial relationship (Professional Services) with Photocure.

has a financial relationship (Ownership Interest) with Amgen; financial relationship (Researcher) with Arrowhead Pharmaceuticals; financial relationship (Ownership Interest) with Biocryst Pharmaceuticals; financial relationship (Advisor) with Bristol Myers Squibb; financial relationship (Researcher) with Bristol Myers Squibb; financial relationship (Researcher) with Calithera Biosciences; financial relationship (Advisor) with Eisai Medical Research; financial relationship (Researcher) with Exelixis; financial relationship (Advisor) with Intellisphere; financial relationship (Advisor) with Ipsen; financial relationship (Ownership Interest) with John & Johnson; financial relationship (Advisor) with Merck; financial relationship (Researcher) with Nektar; financial relationship (Researcher) with Novartis; financial relationship (Researcher) with Oncorena; financial relationship (Ownership Interest) with Spdr S&P Pharmaceuticals; financial relationship (Ownership Interest) with Surface Oncology; financial relationship (Ownership Interest) with Vanguard Health Care ETF.

Faculty

has a financial relationship (Grant Or Contract) with Guardant Health, Precede Biosciences; financial relationship (Speaker) with Guardant Health, Precede Biosciences,; financial relationship (Ownership Interest) with Guardant Health, Precede Biosciences, Genome Medical, Tracer Biotechnologies; financial relationship (Advisor) with Guardant Health, Precede Biosciences, Genome Medical, Tracer Biotechnologies, Musculo; financial relationship (Royalties) with Precede Biosciences; financial relationship (Patent Beneficiary) with Precede Biosciences.

No, I have not had a financial relationship with an ineligible company within the past 24 months.

Awaiting faculty disclosure.

has a financial relationship (Professional Services) with Natera; financial relationship (Professional Services) with EMD Serono; financial relationship (Professional Service) with Arcus Biosciences; financial relationship (Researcher) with Arcus Biosciences; financial relationship (Researcher) with Bristol Myer Squibb; financial relationship (Researcher) with Daiichi Sankyo; financial relationship (Advisor) with Eisai; financial relationship (Researcher) with Kura Oncology; financial relationship (Consultant) with LG Chem; financial relationship (Researcher) with Pfizer.

has a financial relationship (Advisor) with Pfizer; financial relationship (Grant Or Contract) with Astellas; financial relationship (Advisor) with Cardinal Health; financial relationship (Advisor) with Intellisphere; financial relationship (Advisor) with IntrinsiQ Specialty Solutions; financial relationship (Advisor) with Johnson & Johnson; financial relationship (Grant Or Contract) with Merck; financial relationship (Advisor) with Neogenomics; financial relationship (Grant Or Contract) with Pfizer; financial relationship (Grant Or Contract) with Seagen; financial relationship (Grant Or Contract) with Xencor.

Awaiting faculty disclosure.

has a financial relationship (Consultant) with Astra Zeneca; financial relationship (Speaker) with Curio; financial relationship (Speaker) with DAVA Oncology; financial relationship (Researcher) with Duality Biologics; financial relationship (Consultant) with EMD Serono; financial relationship (Researcher) with Exelixis; financial relationship (Researcher) with LOXO at Lilly; financial relationship (Researcher) with Macrogenics; financial relationship (Researcher) with Medicenna; financial relationship (Researcher) with Merck; financial relationship (Consultant) with Pfizer; financial relationship (Researcher) with Pliant Therapeutics; financial relationship (Researcher) with Xencor; financial relationship (Consultant) with Xencor.

has a financial relationship (Advisor) with Merck; financial relationship (Advisor) with Telix; financial relationship (Advisor) with Exelexis.

has a financial relationship (Consultant) with Pfizer; financial relationship (Researcher) with Bristol Myers Squibb Foundation; financial relationship (Consultant) with Johnson & Johnson.

Staff

Awaiting faculty disclosure.